Prosight Management, LP Pro Qr Therapeutics N.V. Transaction History

Prosight Management, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.74 - $0.89 $6,497 - $7,815	8,781 Added 0.51%	1,716,290 $1.28 Million
Q2 2022 Aug 12, 2022	BUY	$0.56 - $1.0 $620,603 - $1.11 Million	1,108,221 Added 184.92%	1,707,509 $1.33 Million
Q1 2022 May 16, 2022	BUY	$0.9 - $8.39 $218,403 - $2.04 Million	242,671 Added 68.05%	599,288 $542,000
Q4 2021 Feb 14, 2022	BUY	$6.58 - $8.44 $489,295 - $627,606	74,361 Added 26.35%	356,617 $2.86 Million
Q3 2021 Nov 12, 2021	SELL	$5.16 - $8.47 $710,759 - $1.17 Million	-137,744 Reduced 32.8%	282,256 $2.36 Million
Q2 2021 Aug 13, 2021	SELL	$5.75 - $7.59 $173,448 - $228,952	-30,165 Reduced 6.7%	420,000 $2.83 Million
Q1 2021 May 14, 2021	BUY	$4.14 - $9.22 $807,983 - $1.8 Million	195,165 Added 76.54%	450,165 $2.98 Million
Q4 2020 Feb 12, 2021	BUY	$3.58 - $4.85 $912,900 - $1.24 Million	255,000 New	255,000 $1.07 Million

17.4M

37.7K

21.3K

Ticker PRQR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,362,096
Market Cap $191M
Description
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...

Get notified when there are updates to the investment portfolio of Prosight Management, LP, based on Form 13F filings with the SEC.

Stay updated on Prosight Management, LP with notifications on news.